A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis

Trial Profile

A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Roxadustat (Primary) ; Darbepoetin alfa; Darbepoetin alfa; Epoetin alfa; Epoetin alfa
  • Indications Anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms Pyrenees
  • Sponsors Astellas Pharma BV
  • Most Recent Events

    • 18 Jul 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2017.
    • 18 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 29 Jun 2015 Approximately 8000 chronic kidney disease patients will be enrolled in this and nine other phase III trials, according to a FibroGen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top